Disease Overview：Mesangial proliferative glomerulonephritis（MesPGN）
Mesangial proliferative glomerulonephritis (MPGN) is a histopathological pattern of primary mesangial cell hyperplasia and increased mesangial matrix deposition, often accompanied by immune complex deposition—typically IgG and C3—within the mesangium. It may present with asymptomatic microscopic hematuria and proteinuria, or progress to nephrotic syndrome, hypertension, and impaired renal function. Diagnosis relies on renal biopsy with light microscopy, immunofluorescence, and electron microscopy to differentiate MPGN from other glomerulopathies such as IgA nephropathy or lupus nephritis. Etiologies include idiopathic causes, chronic infections (e.g., hepatitis B/C), autoimmune disorders, and monoclonal gammopathies. Management focuses on controlling proteinuria, preserving glomerular filtration rate, and addressing underlying triggers—using renin-angiotensin system inhibitors, corticosteroids, and, in select cases, immunosuppressants like mycophenolate mofetil or rituximab. Prognosis varies widely; some patients maintain stable renal function for years, while others develop progressive chronic kidney disease requiring long-term monitoring.
China offers distinct advantages for MPGN management: leading nephrology centers—such as Peking University First Hospital and Shanghai Renji Hospital—combine deep expertise in glomerular disease with advanced diagnostic capabilities, including next-generation immunofluorescence mapping and serial biopsy interpretation. High-field MRI and digital pathology platforms support precise disease stratification and treatment response assessment. Clinical outcomes reflect this strength: over 70% of carefully selected MPGN patients achieve sustained remission or stabilization within 12–24 months under tailored regimens. Treatment costs in China are typically 40–60% lower than in the US or Western Europe, without compromising evidence-based protocols or multidisciplinary care. As a dedicated medical tourism agency, we facilitate seamless international patient journeys—securing appointments with top-tier nephrologists, providing transparent, all-inclusive pricing, coordinating biopsies and follow-up teleconsultations, and offering end-to-end support from visa assistance to post-treatment rehabilitation planning.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Mesangial Proliferative Glomerulonephritis (MPGN)
I. Conservative/Medical Management
*Target Criteria:* Mild proteinuria (<1 g/day), preserved eGFR (>60 mL/min/1.73m²), no active cellular crescents or rapid decline.
- •Baseline Workup (Pre-treatment):
- 24-hr urine protein quantification: $35 - Serum complement C3/C4, ANA, anti-dsDNA, HBV/HCV serology: $180 - eGFR, electrolytes, albumin, lipid panel: $65
- •First-Line Therapy (6–12 months):
- Low-sodium, low-protein diet counseling (nephrology clinic visit ×3): $90 total - Monthly BP monitoring + urine ACR: $20/month
- •Second-Line Immunosuppression (for persistent nephrotic-range proteinuria or declining eGFR):
- Mycophenolate mofetil (1–1.5 g BID): $110–$165/month - Cyclophosphamide (IV pulse × 6 months): $220–$330/course (includes infusion + hydration)
II. Interventional/Procedural Options
*Eligibility:* Rapidly progressive GN (eGFR decline >5 mL/min/yr), crescentic MPGN on biopsy, or steroid-resistant nephrotic syndrome.
- •Plasma Exchange (PLEX)
- *Pre-op workup:* PT/INR, fibrinogen, IgG/IgM levels, central line placement: $210 - *Procedure (1 session, 3–4 L exchange):* $380–$490 - *Typical course:* 10–14 sessions over 2–3 weeks → $4,200–$6,300 total
- •Rituximab Infusion
- *Pre-infusion labs (CD19 count, hepatitis screening):* $140 - *Dose:* 375 mg/m² IV × 4 weekly doses → $2,800–$3,600 total (drug + infusion + monitoring)
III. Special/Complex Scenarios
- •MPGN with Hepatitis B–Associated Nephropathy:
- •Post-Transplant Recurrence:
- •End-Stage Kidney Disease (eGFR <15):
- Peritoneal dialysis setup + monthly supplies: $1,900–$2,400/month
Quick Selection Guide
- •Young adult (<45), mild proteinuria, budget-conscious: ACEi/ARB + diet + monitoring ($200–$350 first year)
- •Middle-aged, nephrotic syndrome, comorbid hypertension/diabetes: Mycophenolate + ACEi ($1,800–$2,500 first year)
- •Elderly (>70), rapid eGFR loss, frailty: PLEX + low-dose prednisone ($5,200–$7,100 first 3 months)
- •HBV-positive MPGN: Entecavir + tapered prednisone ($1,100–$1,600 first year)
- •Recurrent post-transplant MPGN: Rituximab (preferred over eculizumab for cost-effectiveness) ($3,000–$3,800 course)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Mesangial proliferative glomerulonephritis Medical Vacation Packages
Curated transparent all-inclusive packages combining Mesangial proliferative glomerulonephritis treatment with China top medical destinations:
